|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Human interferon alpha/beta receptor chain 2|
|Purification||Ion-exchange chromatography, Size-exclusion chromatography|
|Storage buffer||PBS with 0.1% BSA|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Neutralization (Neu)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Blocking Assay (BLOCK)||See 1 publications below|
This antibody neutralizes human IFN-alpha receptor, interacting with the extracellular domain. It binds to human IFN-alpha receptor with high affinity and blocks biological action of Type I IFNs. To measure bioactivity, interferon was titrated with the use of a cytopathic effect inhibition assay, where one neutralization unit is the amount of antiserum required to neutralize one unit of human interferon alpha to a 50% endpoint. In this antiviral assay, approximately one unit/ml of interferon was necessary to produce a cytopathic effect of 50%.
Purity is >95% by SDS-PAGE and endotoxin level <1 EU/ug.
Store at -20°C for up to 6 months. For long-term storage, store at -70°C for retention of full activity. Thaw product by incubation in cold water and aliquot into separate vials, adding 0.1% BSA for additional stability. Refreeze product using a dry ice or a dry ice/alcohol bath.
The Type I interferon receptor is a heterodimer consisting of IFNAR1 and IFNAR2. The IFNAR2 subunit provides most of the binding affinity for IFN and IFNAR1 is required for optimum signaling.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.
213851 was used in blocking or activating experiment to characterize the role of PD-L1/PD-1 pathway in HIV-1 infection due to immune suppression by neutrophils
|Bowers NL,Helton ES,Huijbregts RP,Goepfert PA,Heath SL,Hel Z||PLoS pathogens (10:null)||2014|